Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-003998
Filing Date
2017-05-09
Accepted
2017-05-09 16:29:30
Documents
57
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vygr-20170331x10q.htm 10-Q 1304018
2 EX-31.1 vygr-20170331ex311bffe4f.htm EX-31.1 21135
3 EX-31.2 vygr-20170331ex312916386.htm EX-31.2 20350
4 EX-32.1 vygr-20170331ex32103fb58.htm EX-32.1 15374
5 GRAPHIC vygr20170331x10q001.jpg GRAPHIC 94972
  Complete submission text file 0001558370-17-003998.txt   5756012

Data Files

Seq Description Document Type Size
6 EX-101.INS vygr-20170331.xml EX-101.INS 1222264
7 EX-101.SCH vygr-20170331.xsd EX-101.SCH 44132
8 EX-101.CAL vygr-20170331_cal.xml EX-101.CAL 50363
9 EX-101.DEF vygr-20170331_def.xml EX-101.DEF 167014
10 EX-101.LAB vygr-20170331_lab.xml EX-101.LAB 374038
11 EX-101.PRE vygr-20170331_pre.xml EX-101.PRE 292117
Mailing Address 75 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 75 SIDNEY STREET CAMBRIDGE MA 02139 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37625 | Film No.: 17826850
SIC: 2836 Biological Products, (No Diagnostic Substances)